© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Sydney Jennings
Articles
Novo Nordisk Seeks FDA Approval for Higher-Dose Semaglutide 7.2 mg for Chronic Weight Management
November 26, 2025
Novo Nordisk submits an FDA application for semaglutide 7.2 mg for chronic weight management, supported by STEP UP trial data showing greater weight loss.
Primary Care Training Boosts LARC Uptake and Long-Term Retention: Daily Dose
November 25, 2025
Your daily dose of the clinical news you may have missed.
Otsuka Submits NDA to FDA for Centanafadine for Treatment of ADHD Across the Lifespan
November 25, 2025
Otsuka seeks FDA approval for centanafadine, a novel ADHD treatment showing significant efficacy and safety in pivotal trials for all age groups.
FDA Approves Itvisma, First Gene Therapy for Older Children and Adults With Spinal Muscular Atrophy
November 25, 2025
Novartis's Itvisma gains FDA approval as the first intrathecal gene therapy for spinal muscular atrophy, promising improved motor function and independence.
Atopic Dermatitis Signs and Symptoms for Referral: Physical and Emotional Expertise
November 25, 2025
Primary care is the ideal setting for management of atopic dermatitis, but certain scenarios, both physical and psychological, call for expert referral.
Long-Term Smoking Cessation Slows Cognitive Decline in Adults: Daily Dose
November 24, 2025
Your daily dose of the clinical news you may have missed.
J&J's Investigational Anti-Tau Alzheimer Drug Posdinemab Fails to Meet Primary Endpoint in Phase 2b Trial
November 24, 2025
J&J halts phase 2b AuTonomy trial after anti-tau antibody posdinemab fails to slow clinical decline, marking another setback for tau-targeting therapeutics.
2025-2026 Flu Season: Reduced Vaccine Match May Lead to Increased Transmission and Severity, Experts Warn
November 24, 2025
The H3N2 subclade K is dominating early flu season gobally; despite vaccine mismatch, vaccination remains the primary defense against severe illness and hospitalization.
HPV Vaccination Strongly Reduces Cervical Cancer Risk, New Cochrane Reviews Confirm
November 24, 2025
Two new Cochrane reviews confirm HPV vaccines significantly reduce cervical cancer risk, especially when given before age 16, with no serious safety concerns.
Semaglutide Fails to Slow Progression of Alzheimer Disease Compared to Placebo: Novo Nordisk Phase 3 Trial Update
November 24, 2025
Evoke trials testing semaglutide for Alzheimer disease missed primary endpoint, failing to demonstrate benefit on cognition despite positive effects on disease markers.